3192 results for «730»

Filter By

3192 results

Real world outcomes and strategies for optimal TEER across diverse DMR anatomies

14 Feb 2026 – From PCR Tokyo Valves 2026

This session develops a nuanced understanding of the complexity inherent in DMR cases, informed by the latest registry data. It highlights the capabilities of the PASCAL device in managing challenging anatomies and achieving predictable clinical results, alongside contemporary strategies for device selection and optimal placement to...

Real world outcomes and strategies for optimal TEER across diverse DMR anatomies

TAVI today and tomorrow: international trends and future direction

14 Feb 2026 – From PCR Tokyo Valves 2026

This session focuses on the evolving landscape of TAVI, emphasising lifetime management strategies with a focus on the first valve implanted. It provides a comprehensive discussion on representative patient profiles, current guidelines from various countries, and future outlooks, alongside recent long-term clinical results for the balloon-expandable...

TAVI today and tomorrow: international trends and future direction

Built to last: lifetime management for durability and beyond

14 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses the principles of lifetime management aimed at durability and optimal long-term outcomes in complex valvular heart disease cases. Key topics include the critical importance of initial valve choice, practical tips for optimizing paravalvular leak (PVL) management, and advanced strategies for redo transcatheter aortic...

Built to last: lifetime management for durability and beyond

Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System

14 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...

Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System

New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL

15 Feb 2026 – From PCR Tokyo Valves 2026

This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...

New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL

Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights

14 Feb 2026 – From PCR Tokyo Valves 2026

Focused on mastering mitral transcatheter edge-to-edge repair (TEER), this session analyzed the 2025 ESC VHD guidelines and their clinical implications. It addressed optimal timing and treatment strategies for severe heart failure beyond the COAPT trial and explored technical solutions for complex anatomies, including customization approaches for...

Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights

PCR @ TCT 2024 - Get the international perspective!

27 Oct 2024

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

PCRonline @ TCT 2024 - get the international perspective!

Femoral artery pseudoaneurysm expansion managed through subcutaneous fat embolization

06 Apr 2021

Femoral artery pseudoaneurysm is a known complication following cardiac catheterization. Rarely, expansion of the pseudoaneurysm can occur and is often catastrophic. We describe a unique method employed by our centre to deal with such a complication.

Raja Ezman Raja

Author

Raja Ezman Raja
Femoral artery pseudoaneurysm expansion managed through subcutaneous fat embolization

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

18 May 2021

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Yohei Ohno

Author

Yohei Ohno
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

18 Sep 2022

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Jonathan Curio

Author

Jonathan Curio
The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial

05 Mar 2023

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Luigi Biasco

Author

Luigi Biasco
Transcatheter versus surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut low risk Trial
Didn’t find what you were looking for?